vs

Side-by-side financial comparison of Bioventus Inc. (BVS) and PROGRESS SOFTWARE CORP (PRGS). Click either name above to swap in a different company.

PROGRESS SOFTWARE CORP is the larger business by last-quarter revenue ($252.7M vs $157.9M, roughly 1.6× Bioventus Inc.). PROGRESS SOFTWARE CORP runs the higher net margin — 10.2% vs 9.3%, a 0.8% gap on every dollar of revenue. On growth, PROGRESS SOFTWARE CORP posted the faster year-over-year revenue change (17.5% vs 2.8%). PROGRESS SOFTWARE CORP produced more free cash flow last quarter ($59.9M vs $37.4M). Over the past eight quarters, PROGRESS SOFTWARE CORP's revenue compounded faster (17.0% CAGR vs 10.4%).

Bioventus Inc. is a global medical technology company specializing in orthobiologic solutions. It develops and commercializes products supporting bone and joint healing, musculoskeletal pain management, and regenerative care for patients. Its offerings serve orthopedic clinicians, physical therapists, and patients across North America, Europe, and Asia Pacific, with core segments covering surgical orthobiologics and non-surgical pain relief solutions.

Progress Software Corporation develops and sells enterprise software products including application development platforms, data connectivity tools, and digital experience solutions. It serves global enterprise clients across finance, healthcare, manufacturing, retail and other sectors, helping organizations build scalable, high-performance business applications and streamline operational workflows.

BVS vs PRGS — Head-to-Head

Bigger by revenue
PRGS
PRGS
1.6× larger
PRGS
$252.7M
$157.9M
BVS
Growing faster (revenue YoY)
PRGS
PRGS
+14.8% gap
PRGS
17.5%
2.8%
BVS
Higher net margin
PRGS
PRGS
0.8% more per $
PRGS
10.2%
9.3%
BVS
More free cash flow
PRGS
PRGS
$22.5M more FCF
PRGS
$59.9M
$37.4M
BVS
Faster 2-yr revenue CAGR
PRGS
PRGS
Annualised
PRGS
17.0%
10.4%
BVS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BVS
BVS
PRGS
PRGS
Revenue
$157.9M
$252.7M
Net Profit
$14.8M
$25.7M
Gross Margin
68.9%
81.6%
Operating Margin
12.3%
15.2%
Net Margin
9.3%
10.2%
Revenue YoY
2.8%
17.5%
Net Profit YoY
3902.8%
2144.6%
EPS (diluted)
$0.21
$0.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BVS
BVS
PRGS
PRGS
Q4 25
$157.9M
$252.7M
Q3 25
$138.7M
$249.8M
Q2 25
$147.7M
$237.4M
Q1 25
$123.9M
$238.0M
Q4 24
$153.6M
$215.0M
Q3 24
$139.0M
$178.7M
Q2 24
$151.2M
$175.1M
Q1 24
$129.5M
$184.7M
Net Profit
BVS
BVS
PRGS
PRGS
Q4 25
$14.8M
$25.7M
Q3 25
$3.2M
$19.4M
Q2 25
$7.5M
$17.0M
Q1 25
$-2.6M
$10.9M
Q4 24
$-388.0K
$1.1M
Q3 24
$-5.2M
$28.5M
Q2 24
$-25.7M
$16.2M
Q1 24
$-4.9M
$22.6M
Gross Margin
BVS
BVS
PRGS
PRGS
Q4 25
68.9%
81.6%
Q3 25
68.0%
81.0%
Q2 25
69.1%
80.1%
Q1 25
67.0%
80.6%
Q4 24
66.8%
83.0%
Q3 24
67.3%
83.7%
Q2 24
68.5%
81.7%
Q1 24
68.3%
82.2%
Operating Margin
BVS
BVS
PRGS
PRGS
Q4 25
12.3%
15.2%
Q3 25
8.1%
17.6%
Q2 25
12.4%
16.3%
Q1 25
3.9%
13.6%
Q4 24
5.0%
10.0%
Q3 24
2.6%
22.6%
Q2 24
-20.8%
15.5%
Q1 24
3.8%
19.0%
Net Margin
BVS
BVS
PRGS
PRGS
Q4 25
9.3%
10.2%
Q3 25
2.3%
7.8%
Q2 25
5.1%
7.2%
Q1 25
-2.1%
4.6%
Q4 24
-0.3%
0.5%
Q3 24
-3.7%
15.9%
Q2 24
-17.0%
9.2%
Q1 24
-3.8%
12.3%
EPS (diluted)
BVS
BVS
PRGS
PRGS
Q4 25
$0.21
$0.59
Q3 25
$0.05
$0.44
Q2 25
$0.11
$0.39
Q1 25
$-0.04
$0.24
Q4 24
$0.00
$0.01
Q3 24
$-0.08
$0.65
Q2 24
$-0.40
$0.37
Q1 24
$-0.08
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BVS
BVS
PRGS
PRGS
Cash + ST InvestmentsLiquidity on hand
$51.2M
$94.8M
Total DebtLower is stronger
$1.4B
Stockholders' EquityBook value
$184.1M
$478.3M
Total Assets
$683.6M
$2.5B
Debt / EquityLower = less leverage
2.93×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BVS
BVS
PRGS
PRGS
Q4 25
$51.2M
$94.8M
Q3 25
$42.2M
$99.0M
Q2 25
$32.9M
$102.0M
Q1 25
$22.8M
$124.2M
Q4 24
$41.6M
$118.1M
Q3 24
$43.1M
$232.7M
Q2 24
$32.0M
$190.4M
Q1 24
$25.2M
$133.2M
Total Debt
BVS
BVS
PRGS
PRGS
Q4 25
$1.4B
Q3 25
$1.4B
Q2 25
$1.5B
Q1 25
$1.5B
Q4 24
$1.5B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BVS
BVS
PRGS
PRGS
Q4 25
$184.1M
$478.3M
Q3 25
$166.1M
$477.7M
Q2 25
$161.2M
$452.7M
Q1 25
$148.1M
$431.8M
Q4 24
$147.9M
$438.8M
Q3 24
$148.7M
$425.6M
Q2 24
$150.9M
$401.7M
Q1 24
$171.3M
$461.7M
Total Assets
BVS
BVS
PRGS
PRGS
Q4 25
$683.6M
$2.5B
Q3 25
$701.6M
$2.4B
Q2 25
$706.8M
$2.4B
Q1 25
$691.4M
$2.5B
Q4 24
$728.0M
$2.5B
Q3 24
$769.5M
$1.6B
Q2 24
$792.2M
$1.6B
Q1 24
$794.2M
$1.5B
Debt / Equity
BVS
BVS
PRGS
PRGS
Q4 25
2.93×
Q3 25
2.97×
Q2 25
3.22×
Q1 25
3.50×
Q4 24
3.48×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BVS
BVS
PRGS
PRGS
Operating Cash FlowLast quarter
$38.0M
$62.8M
Free Cash FlowOCF − Capex
$37.4M
$59.9M
FCF MarginFCF / Revenue
23.7%
23.7%
Capex IntensityCapex / Revenue
0.4%
1.1%
Cash ConversionOCF / Net Profit
2.57×
2.44×
TTM Free Cash FlowTrailing 4 quarters
$72.1M
$229.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BVS
BVS
PRGS
PRGS
Q4 25
$38.0M
$62.8M
Q3 25
$30.1M
$73.4M
Q2 25
$25.9M
$30.0M
Q1 25
$-19.3M
$68.9M
Q4 24
$19.3M
$19.7M
Q3 24
$10.3M
$57.7M
Q2 24
$15.2M
$63.7M
Q1 24
$-6.0M
$70.5M
Free Cash Flow
BVS
BVS
PRGS
PRGS
Q4 25
$37.4M
$59.9M
Q3 25
$29.6M
$72.4M
Q2 25
$25.3M
$29.5M
Q1 25
$-20.2M
$67.7M
Q4 24
$18.7M
$16.8M
Q3 24
$10.3M
$56.6M
Q2 24
$15.1M
$62.7M
Q1 24
$-6.3M
$70.2M
FCF Margin
BVS
BVS
PRGS
PRGS
Q4 25
23.7%
23.7%
Q3 25
21.4%
29.0%
Q2 25
17.1%
12.4%
Q1 25
-16.3%
28.4%
Q4 24
12.2%
7.8%
Q3 24
7.4%
31.7%
Q2 24
10.0%
35.8%
Q1 24
-4.9%
38.0%
Capex Intensity
BVS
BVS
PRGS
PRGS
Q4 25
0.4%
1.1%
Q3 25
0.3%
0.4%
Q2 25
0.5%
0.2%
Q1 25
0.7%
0.5%
Q4 24
0.4%
1.3%
Q3 24
0.0%
0.6%
Q2 24
0.1%
0.5%
Q1 24
0.2%
0.2%
Cash Conversion
BVS
BVS
PRGS
PRGS
Q4 25
2.57×
2.44×
Q3 25
9.54×
3.78×
Q2 25
3.48×
1.76×
Q1 25
6.30×
Q4 24
17.13×
Q3 24
2.03×
Q2 24
3.93×
Q1 24
3.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BVS
BVS

Pain Treatments$71.1M45%
Surgical Solutions$48.9M31%
Restorative Therapies$19.5M12%
Other$18.4M12%

PRGS
PRGS

Maintenanceand Services$187.5M74%
Share File Acquisition$67.5M27%

Related Comparisons